When was invIOs founded?

invIOs was founded in 2019 and raised its 1st funding round 5 years after it was founded.

Where is invIOs located?

invIOs is headquartered in Vienna, Austria.

Who is the current CEO of invIOs?

Peter Llewellyn-Davies of invIOs.

How many employees does invIOs have?

As of Apr 30, 2026, the latest employee count at invIOs is 14.

Is invIOs a funded company?

invIOs is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Oct 15, 2024.

When was the latest funding round of invIOs?

invIOs' latest funding was a $***** Series A round on Oct 15, 2024, with participation from 1 investor. Its primary sector is Oncology. Globally, the Oncology sector has seen $3.73B in funding in 2026 to date.

Where does invIOs rank among its competitors?

invIOs ranks 861st amongst 3270 active competitors, of which 1128 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Senti Biosciences, which secured $40M in May, 2026.

Who are the top competitors of invIOs?

invIOs' top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Senti Biosciences secured the most recent funding round in May, 2026.

invIOs - 2026 Company Profile, Team, Funding & Competitors

invIOs is a series A company based in Vienna (Austria), founded in 2019. It operates as a Developer of immunotherapies for the treatment of cancer. invIOs has raised $8.95M in funding from Ligand Pharmaceuticals. The company has 3270 active competitors, including 1128 funded and 772 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of immunotherapies for the treatment of cancer. The company has a proprietary cell therapy technology platform for the modulation of intracellular Immuno-Oncology targets enabling rapid treatment of patients using their own cells. The lead candidate of the company is APN401 for the treatment of solid tumors. Other drug candidates include INV441 and INV501, an early-stage cell therapy approach to activate tumor-associated immune cells.

Website: www.invios.com
Social
Email ID: *****@invios.com
Phone Number: +43 **********

Key Metrics

Founded Year

2019

Location

Vienna, Austria

Stage

Series A

Total Funding

$8.95M in 1 round

Latest Funding Round

Series A, Oct 15, 2024, $*****

Investors

Ligand Pharmaceuticals

Ranked

861^st among 3270 active competitors

Employee Count

14 as on Apr 30, 2026

Similar Companies

BeiGene & 584 more

View invIOs' full profile

invIOs has raised a total funding of $8.95M over 1 round. Its latest funding round was a Series A round on Oct 15, 2024 for $*****. 1 investor participated in its latest round. invIOs has 1 institutional investor.

Here is the list of recent funding rounds of invIOs:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 15, 2024	1570335	Series A	1344637	9974300	3132199	2980479

Access funding benchmarks and valuations. Sign up today!

View details of invIOs's funding rounds and investors

invIOs' employee count trend

invIOs has 14 employees as of Apr 26. Here is invIOs's employee count trend over the years:

Uncover invIOs' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of invIOs include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of invIOs, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
4th	Senti Biosciences 2016, San Francisco (United States), Public	Developer of cell-based therapies for cancer treatment	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
7th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
861st	invIOs 2019, Vienna (Austria), Series A	Developer of immunotherapies for the treatment of cancer	$8.95M	Ligand Pharmaceuticals	44/100